...
...
...
Next StoryDown Arrow

Novel RNA factors may help cancer cells thrive

Recent work by researchers at Brigham and Women's Hospital pinpoints critical changes in an enzyme known as DICER, which create a cascade of effects on this microRNAome.

Published on: Jan 11, 2021 03:13 pm IST
ANI |
Advertisement

Recent work by researchers at Brigham and Women's Hospital pinpoints critical changes in an enzyme known as DICER, which create a cascade of effects on this microRNAome.

Recent work by researchers at Brigham and Women's Hospital pinpoints critical changes in an enzyme known as DICER, which create a cascade of effects on this microRNAome.(Yahoo)

The team identified primary actors circ2082, a circular RNA, and RBM3, an RNA-binding protein, which form a complex with DICER to trap it in the nucleus of glioblastoma cells, therefore disrupting the cytoplasmic microRNAome.

Findings are published in Science Advances.

"We are always trying to find the magic bullet to fight cancer. The problem with the magic bullet is that it's only going to hit a few tumor cells, since the other tumor cells don't have that target. We are looking for the common vulnerability -- what is the common thing that we can target?" said Antonio Chiocca, MD, PhD, chair of the Brigham's Department of Neurosurgery.

"With this discovery, we can target something way upstream: a very common target at the epigenetic level," added Chiocca.

The level of microRNA expression in these mice changed their survival rates. If circ2082 was knocked down, the nuclear DICER complex of circ2082, DICER, and RBM3 was disrupted, more microRNAs were present in the cytoplasm, and the survival outcome was far greater.

In these mice whose tumours had circ2082 knocked down, death by tumorigenesis never occurred, while their non-knockdown counterparts all experienced death by tumorigenesis.

The downstream effect of this circ2082 expression also heavily influenced morbidity in human patients whose tissues were retrospectively analysed. Patients with circ2082-dependent signature-less widely expressed had overall longer lifespans after a cancer diagnosis.

"Targeting these upstream tumour proliferators has the potential to dramatically change the cancer treatment landscape. We look forward to the clinical translation of this research as we search for the right inhibitors," said Chiocca.

Follow more stories on Facebook and Twitter

This story has been published from a wire agency feed without modifications to the text.

 
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
Catch every big hit, every wicket with Crick-it, a one stop destination for Live Scores, Match Stats, Quizzes, Polls & much more. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
SHARE THIS ARTICLE ON
Subscribe Now